NovaBay Pharmaceuticals, Inc. — Director's Dealing 2021

Nov 18, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NovaBay Pharmaceuticals, Inc. (NBY)
CIK: 0001389545
Period of Report: 2021-11-05

Reporting Person: Kunin Jeffrey (President, DERMAdoctor, LLC)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	0	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock option (right to buy)	$0.5597	2031-11-05	Common Stock (150000)		Indirect

Footnotes

F1: The stock option grant will vest in two tranches, with 50% vesting on November 5, 2022 and 50% vesting on November 5, 2023.